PARIS, France, January 31, 2023 – 6:00 p.m. (CET) – Abivax SA (Euronext Paris: FR0012333284 – ABVX),
Phase 3 clinical-stage biotechnology company developing drugs that modulate the
immune system to treat patients with chronic inflammatory diseases announces
today the reset of the conversion/exchange ratio of convertible/exchangeable bonds
in new and/or existing shares (OCEANEs) maturing in 2026 for a nominal amount of 24,999,975.99
euros, issued by Abivax SA (ISIN FR0014004PT4)